Product concentration
Substantially all revenue comes from a limited set of products, especially Zephyr Valve.
- Scope
- If Zephyr adoption slows, revenue growth and operating leverage weaken.
- Materiality
- high
Pulmonx Corp
Pulmonx Corp is a U.S.-based medical device company focused on minimally invasive treatments for severe emphysema and other advanced chronic obstructive pulmonary disease (COPD) patients. Its portfolio centers on the Zephyr Endobronchial Valve, supported by the Chartis assessment system, LungTraX patient identification software, and the AeriSeal System under development and clinical evaluation.
−58,1 %
74,2 %
−59,7 %
+8,0 %
5.07
4.28
| % | |
|---|---|
| Zephyr Valve therapy | 80% Endobronchial valves and delivery tools used to treat severe emphysema. |
| Chartis assessment system | 12% Diagnostic and procedural tools used to assess collateral ventilation and guide treatment. |
| Digital patient identification | 0% LungTraX software used to identify patients who may be eligible for Zephyr treatment. |
| AeriSeal program | 8% Synthetic polymer foam system under clinical development for lung lobe occlusion. |
Pulmonx sells primarily to hospitals, interventional pulmonologists, and distributors that support bronchoscopic lung...
- Hospitals and health systemsprimary
Buy valves, catheters, and Chartis tools to establish and expand emphysema treatment programs.
- Interventional pulmonologistsprimary
Use the system in procedures and drive clinical adoption through patient selection and treatment.
- International distributorssecondary
Purchase and resell products in select markets where direct sales are not used.
- Patients and referring clinicianssecondary
Influence demand through diagnosis, referral, and awareness of minimally invasive treatment options.
Pulmonx is headquartered in the United States and sells through a direct commercial organization there, while...
- •United States is the core commercial market and direct-sales base
- •International sales are split between direct and distributor channels
- •Europe is important for reimbursement-backed adoption
- •Asia Pacific and other markets add growth but require local execution
- •Foreign currency movements affect reported international revenue
Pulmonx is focused on expanding Zephyr Valve adoption by building hospital programs, training physicians, and...
01
Expand U.S. procedure volumesshort-term
The core growth lever is broader physician and hospital adoption of Zephyr Valve therapy.
02
Strengthen reimbursement and clinical evidencemedium-term
Coverage and published outcomes are critical for hospital uptake and payer acceptance.
03
Expand international commercializationmedium-term
International markets provide additional procedure volume but require local execution and reimbursement readiness.
04
Develop next-generation productslong-term
Pipeline expansion can increase the addressable market and reduce reliance on one product family.
Pulmonx is exposed to adoption risk because its business depends heavily on one core therapy, physician training, and...
Reimbursement dependence
Procedures require coding, coverage, and payment support to be broadly adopted.
- Scope
- Changes in payer policy can reduce hospital willingness to offer the procedure.
- Materiality
- high
Clinical and product liability
The therapy is used in invasive procedures on high-risk COPD patients.
- Scope
- Adverse events or weak clinical evidence could slow adoption.
- Materiality
- high
Limited commercial experience
The company states it has limited experience marketing and selling its solution.
- Scope
- Sales execution and physician education are central to growth.
- Materiality
- medium
International execution
Markets outside the U.S. require local reimbursement, regulatory, and channel management.
- Scope
- Distributor performance and local market access can vary significantly.
- Materiality
- medium
Revenue recognition
Can shift revenue between periods depending on shipment and usage timing
Seasonality
Quarterly revenue and margins may not be directly comparable
Lease accounting
Impacts liabilities, expense recognition, and liquidity analysis
Debt and financing obligations
Affects leverage, interest expense, and covenant monitoring
Clinical-development and regulatory estimates
Can affect capitalization, expense timing, and future asset values
: 29.4.2026